Dactolisib

Dactolisib

Names
IUPAC name 2-Methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile
Other names NVP-BEZ235; BEZ-235
Identifiers
CAS Number	915019-65-7 N
3D model (Jmol)	Interactive image
ChemSpider	10151099 Y
IUPHAR/BPS	7950
KEGG	D10552
PubChem CID	11977753
InChI InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3 Y Key: JOGKUKXHTYWRGZ-UHFFFAOYSA-N Y
SMILES N#CC(c6ccc(N5c4c(cnc3ccc(c1cc2ccccc2nc1)cc34)N(C5=O)C)cc6)(C)C
Properties
Chemical formula	C30H23N5O
Molar mass	469.55 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N  (what is YN ?)
Infobox references

Dactolisib (codenamed NVP-BEZ235 and BEZ-235) is an imidazoquinoline derivative acting as a PI3K inhibitor. It also inhibits mTOR. It is being investigated as a possible cancer treatment.

It has been shown to be toxic to Waldenström's macroglobulinemia cells.

It was the first PI3K inhibitor to enter clinical trials, in 2006.

A phase IB/II clinical trial for locally advanced or metastatic HER2 negative breast cancer has completed.

A phase II clinical trial for advanced pancreatic neuroendocrine tumors (pNET) has reported results.